SCHEMBL35082

SCHEMBL35082

[CH]1CCC2CCCC12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16241604 1.00
SCHEMBL3292869 1.00
SCHEMBL35146 0.94
SCHEMBL9005258 0.94
SCHEMBL8701172 0.92 ALDH1A1 (0.37)
SCHEMBL35197 0.92 ALDH1A1 (0.37)
SCHEMBL55986 0.88
SCHEMBL55987 0.88
SCHEMBL56170 0.88
SCHEMBL25222531 0.86 ALDH1A1 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2476 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024140637-A1 OXOISOINDOLINYL SUBSTITUTED PIPERIDINEDIONE DERIVATIVE AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-07-04 WO claimed
WO-2024140638-A1 COMPOUND BASED ON SULFUR/OXYGEN SUBSTITUTED GLUTARIMIDE-BASED ISOINDOLINONE SKELETON AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-07-04 WO claimed
WO-2024109671-A1 CAS9 PROTEIN, VARIANTS, OR HOMOLOGUES THEREOF-SPECIFIC PROTAC DEGRADERS AND USES THEREOF GLUETACS THERAPEUTICS (SHANGHAI) CO., LTD. (CN) 2024-05-30 WO claimed
WO-2023091554-A9 NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS ICAGEN, LLC (US) 2024-05-23 WO claimed
WO-2024078555-A1 PYRIMIDOPYRIDINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 广东东阳光药业股份有限公司 2024-04-18 WO claimed
CN-117886833-A Pyrimidopyridine compound, pharmaceutical composition and application thereof 广东东阳光药业股份有限公司 2024-04-16 CN claimed
CN-117881668-A Compound based on isoindoline substituted glutarimide skeleton and application thereof 标新生物医药科技(上海)有限公司 2024-04-12 CN claimed
CN-117586180-A Compounds useful as inhibitors of voltage-gated sodium channels 广州费米子科技有限责任公司 2024-02-23 CN claimed
US-20230382854-A1 Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds and Their Derivatives, Processes for Their Preparation and Therapeutic Uses Thereof SANOFI (FR) 2023-11-30 US claimed
EP-4228758-A1 SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF Sanofi (FR) 2023-08-23 EP claimed
EP-2051712-A2 MODULATORS OF MUSCARINIC RECEPTORS Vertex Pharmceuticals Incorporated (US) 2009-04-29 EP claimed
WO-2009039127-A1 URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C ABBOTT LABORATORIES (US) 2009-03-26 WO claimed
EP-1975611-A1 Agonists of bitter taste receptors and uses thereof Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand (DE) 2008-10-01 EP claimed
US-20080176843-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2008-07-24 US claimed
WO-2008021375-A2 MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-02-21 WO claimed
US-20030176445-A1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists PFIZER INC. 2003-09-18 US claimed
EP-1106615-B1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists PFIZER (US) 2003-03-05 EP claimed
US-20020042421-A1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists OKUMURA YOSHIYUKI (JP) 2002-04-11 US claimed
EP-1106615-A1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists PFIZER INC. (US) 2001-06-13 EP claimed
EP-0421752-A2 Substituted acrylamido-penicillanic acid derivatives Beecham Group p.l.c. (GB) 1991-04-10 EP claimed